November 20, 2015

New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence

Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone November 20, 2015 04:01… Read More
learn more
November 20, 2015

New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence

Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone November 20, 2015 04:01… Read More
learn more
November 20, 2015

New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence

Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone November 20, 2015 04:01… Read More
learn more
November 17, 2015

Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data

Quality of life was maintained throughout treatment with Tumor Treating Fields Quality of life was maintained throughout treatment with Tumor Treating Fields EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who… Read More
learn more
November 17, 2015

Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data

Quality of life was maintained throughout treatment with Tumor Treating Fields Quality of life was maintained throughout treatment with Tumor Treating Fields EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who… Read More
learn more
November 17, 2015

Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data

Quality of life was maintained throughout treatment with Tumor Treating Fields Quality of life was maintained throughout treatment with Tumor Treating Fields EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who… Read More
learn more
November 17, 2015

Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015

November 17, 2015 07:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning… Read More
learn more
November 17, 2015

Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015

November 17, 2015 07:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning… Read More
learn more
November 17, 2015

Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015

November 17, 2015 07:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning… Read More
learn more